Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (Mk-8835/PF-04971729) In Subjects With Type 2 Diabetes Mellitus And Established Vascular Disease
Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Active
The Overall Study Sponsor has developed a study to evaluate the cardiovascular safety of ertugliflozin compared with a non-ertugliflozin comparator group and to assess the safety and tolerability of ertugliflozin and its effects on measures of glycemic control, blood pressure, body weight, renal function and albuminuria
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.